Free Trial
NASDAQ:NGNE

Neurogene (NGNE) Stock Price, News & Analysis

Neurogene logo
$10.03 -0.43 (-4.11%)
As of 12:26 PM Eastern

About Neurogene Stock (NASDAQ:NGNE)

Key Stats

Today's Range
$9.37
$10.54
50-Day Range
$9.65
$23.30
52-Week Range
$9.22
$74.49
Volume
66,000 shs
Average Volume
212,920 shs
Market Capitalization
$149.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.80
Consensus Rating
Buy

Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Remove Ads

Neurogene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

NGNE MarketRank™: 

Neurogene scored higher than 50% of companies evaluated by MarketBeat, and ranked 545th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurogene has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neurogene has only been the subject of 2 research reports in the past 90 days.

  • Read more about Neurogene's stock forecast and price target.
  • Earnings Growth

    Earnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurogene is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurogene is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neurogene has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Neurogene's valuation and earnings.
  • Percentage of Shares Shorted

    12.59% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Neurogene has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neurogene does not currently pay a dividend.

  • Dividend Growth

    Neurogene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.59% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Neurogene has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Neurogene has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Neurogene this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,247.00 in company stock.

  • Percentage Held by Insiders

    Only 9.92% of the stock of Neurogene is held by insiders.

  • Percentage Held by Institutions

    52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurogene's insider trading history.
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

NGNE Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
What is HC Wainwright's Estimate for Neurogene Q1 Earnings?
See More Headlines

NGNE Stock Analysis - Frequently Asked Questions

Neurogene's stock was trading at $22.86 at the beginning of 2025. Since then, NGNE stock has decreased by 57.3% and is now trading at $9.7690.
View the best growth stocks for 2025 here
.

Neurogene Inc. (NASDAQ:NGNE) announced its quarterly earnings results on Monday, March, 24th. The company reported ($0.99) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter.

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
3/24/2025
Today
4/03/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.80
High Stock Price Target
$72.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+471.7%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,320,000.00
Pretax Margin
-5,756.43%

Debt

Sales & Book Value

Annual Sales
$925,000.00
Price / Cash Flow
N/A
Book Value
$14.51 per share
Price / Book
0.72

Miscellaneous

Free Float
13,381,000
Market Cap
$156.17 million
Optionable
Optionable
Beta
1.01
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:NGNE) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners